Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

17.820
+0.0600.34%
Volume:1.70M
Turnover:30.77M
Market Cap:18.91B
PE:-41.97
High:18.680
Open:17.520
Low:17.520
Close:17.760
52wk High:18.750
52wk Low:4.900
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:2.12
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.425
ROE:-18.45%
ROA:-14.45%
PB:8.52
PE(LYR):-41.97
PS:8127.45

Loading ...

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31

Stock News
·
Oct 31, 2025

Ascletis Pharma Files HKEX Disclosure on Repurchase of 200,000 Shares at HKD 1,932,670

Reuters
·
Oct 31, 2025

HK Movers|Biotech Shares Soar. 3SBIO up 11%; RemeGen up 8%; SKB BIO up 7%; Junshi Bio up 5%; Hengrui Pharma and Innocare up 4%.

Tiger Newspress
·
Oct 31, 2025

Hong Kong Stocks Movement | ASCLETIS-B (01672) Rises Over 4% as Subcutaneous Amylin Receptor Agonist ASC36 Enters Clinical Development

Stock News
·
Oct 31, 2025

Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

Reuters
·
Oct 30, 2025

ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development

Stock News
·
Oct 30, 2025

Ascletis Pharma Inc. (1672) Announces Once-Monthly Amylin Receptor Agonist ASC36 for Clinical Development

Bulletin Express
·
Oct 30, 2025

HK Stock Buyback Summary | October 29

Stock News
·
Oct 29, 2025

Ascletis Pharma (01672) Announces Update on Share Repurchase and Treasury Share Changes

Bulletin Express
·
Oct 28, 2025

ASCLETIS-B (01672) Repurchased 100,000 Shares for HK$918,900 on October 28

Stock News
·
Oct 28, 2025

Ascletis Pharma Repurchases 100,000 Shares for HKD 918,910 in HKEX Disclosure

Reuters
·
Oct 28, 2025

Ascletis Pharma to Present Obesity Drug Study Findings at Georgia Conference

MT Newswires Live
·
Oct 27, 2025

Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares

Bulletin Express
·
Oct 27, 2025

Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025

Bulletin Express
·
Oct 27, 2025

ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025

Stock News
·
Oct 27, 2025

Assessing Ascletis Pharma (SEHK:1672) Valuation After Strong Share Price Surge

Simply Wall St.
·
Oct 25, 2025

Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial

Reuters
·
Oct 24, 2025

Ascletis Pharma Inc. (01672) Releases Next Day Disclosure Return on Share Repurchases

Bulletin Express
·
Oct 23, 2025

Hong Kong Stock Buyback Statistics | October 23

Stock News
·
Oct 23, 2025

Ascletis Pharma Repurchases 100,000 Shares for HKD 926,520 in HKEX Disclosure Return

Reuters
·
Oct 22, 2025